Anti Human IgG [R10Z8E9]

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: Anti Human IgG [R10Z8E9]
• Alternate name: IgG, Immunoglobulin G,
• Research fields: Cancer;Immunology
• Tool sub type: Secondary antibody
• Class: Monoclonal
• Conjugation: Unconjugated
• Strain: Balb/c
• Host: Mouse
• Application: ELISA ; IHC ; WB
• Description: Monoclonal antibody specific for human immunoglobulin G. Background and Research Application: Antibodies make up a major component of humoral immunity, with Immunoglobulin G making up the main type found circulating in blood and extracellular fluid allowing permitting access to the body's tissues to control infection through binding pathogens like viruses, bacteria, and fungi. IgG is a type of antibody, has two antigen binding sites, and represents approximately 75% of serum antibodies in humans. IgG is the most common type of antibody found in the circulation and they are created and released by plasma B cells. This antibody is specific for human IgG.
• Immunogen: Human IgM rheumatoid factor Waldenstrom's macroglobulineamia
• Immunogen uniprot id: P01857
• Isotype: IgG1
• Myeloma used: NS0

Target Details

• Target: Human immunoglobulin G - all subclasses
• Target background: Monoclonal antibody specific for human immunoglobulin G. Background and Research Application: Antibodies make up a major component of humoral immunity, with Immunoglobulin G making up the main type found circulating in blood and extracellular fluid allowing permitting access to the body's tissues to control infection through binding pathogens like viruses, bacteria, and fungi. IgG is a type of antibody, has two antigen binding sites, and represents approximately 75% of serum antibodies in humans. IgG is the most common type of antibody found in the circulation and they are created and released by plasma B cells. This antibody is specific for human IgG.

Applications

• Application: ELISA ; IHC ; WB
• Application notes: This reagent may not be used for the detection of a therapeutic antibody in an experimental animal without prior consent by the owner of EP 1853921 (F. Hoffmann-La Roche AG, Basel, Switzerland) and /or US 7,955,806 (HOFFMANN-LA ROCHE, INC., Nutley, NJ).

Handling

• Format: Liquid
• Concentration: 1 mg/ml
• Unit size: 100 ug
• Storage buffer: PBS with 0.02% azide
• Storage conditions: Store at -20° C frozen. Avoid repeated freeze / thaw cycles
• Shipping conditions: Shipping at 4° C

References

• Zhang et al. 2016. J Biol Chem. 291(16):8475-85. PMID: 26917724.
• Laumet et al. 2015. Nat Neurosci. 18(12):1746-55. PMID: 26551542.
• Zhang et al. 2015. J Biol Chem. 290(23):14647-55. PMID: 25925949.
• Stubenrauch et al. 2010. J Pharm Biomed Anal. 52(2):249-54. PMID: 20083366.
• Stubenrauch et al. 2010. Drug Metab Dispos. 38(1):84-91. PMID: 19850673.
• Evaluation of a generic immunoassay with drug tolerance to detect immune complexes in serum samples from cynomolgus monkeys after administration of human antibodies.
• Impact of molecular processing in the hinge region of therapeutic IgG4 antibodies on disposition profiles in cynomolgus monkeys.
• Stubenrauch et al. 2009. J Pharm Biomed Anal. 49(4):1003-8. PMID: 19250787.
• Evaluation of an immunoassay for human-specific quantitation of therapeutic antibodies in serum samples from non-human primates.
• Yang et al. 2008. J Immunol Methods. 335(1-2):8-20. PMID: 18402977.
• Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
• Lund et al. 2000. Eur J Biochem. 267(24):7246-57. PMID: 11106438.
• Expression and characterization of truncated forms of humanized L243 IgG1. Architectural features can influence synthesis of its oligosaccharide chains and affect superoxide production triggered through human Fcgamma receptor I.
• Lund et al. 1996. J Immunol. 157(11):4963-9. PMID: 8943402.
• Multiple interactions of IgG with its core oligosaccharide can modulate recognition by complement and human Fc gamma receptor I and influence the synthesis of its oligosaccharide chains.
• Akinwolere et al. 1994. J Clin Pathol. 47(5):405-10. PMID: 8027392.
• Two enzyme linked immunosorbent assays for detecting antibodies against meningococcal capsular polysaccharides A and C.
• Hazlewood et al. 1993. Clin Exp Immunol. 93(2):157-64. PMID: 8348740.
• The acquisition of anti-pneumococcal capsular polysaccharide Haemophilus influenzae type b and tetanus toxoid antibodies, with age, in the UK.